{
    "id": 19000,
    "fullName": "RHEB over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "RHEB over exp indicates an over expression of the Rheb protein. However, the mechanism causing the overexpression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6009,
        "geneSymbol": "RHEB",
        "terms": [
            "RHEB",
            "RHEB2"
        ]
    },
    "variant": "over exp",
    "createDate": "03/02/2016",
    "updateDate": "03/02/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4870,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lonafarnib (SCH66336) treatment enhanced Taxotere (docetaxel)-induced caspase activation in ovarian cancer cell lines overexpressing Rheb in culture (PMID: 16006564).",
            "molecularProfile": {
                "id": 19404,
                "profileName": "RHEB over exp"
            },
            "therapy": {
                "id": 3665,
                "therapyName": "Docetaxel + Lonafarnib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4762,
                    "pubMedId": 16006564,
                    "title": "The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16006564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4871,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lonafarnib (SCH66336) treatment enhanced Nolvadex (tamoxifen)-induced apoptosis in breast cancer cell lines overexpressing Rheb in culture (PMID: 16006564).",
            "molecularProfile": {
                "id": 19404,
                "profileName": "RHEB over exp"
            },
            "therapy": {
                "id": 3664,
                "therapyName": "Lonafarnib + Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4762,
                    "pubMedId": 16006564,
                    "title": "The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16006564"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4866,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment inhibited survival of patient-derived lymphoma cells harboring TP53 inactivating mutation, MYC rearrangement, and RHEB overexpression (PMID: 18708578).",
            "molecularProfile": {
                "id": 19405,
                "profileName": "MYC rearrange RHEB over exp TP53 inact mut"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4865,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) and Adriamycin (doxorubicin) combination treatment inhibited survival of patient-derived lymphoma cells harboring TP53 inactivating mutation, MYC rearrangement, and RHEB overexpression (PMID: 18708578).",
            "molecularProfile": {
                "id": 19405,
                "profileName": "MYC rearrange RHEB over exp TP53 inact mut"
            },
            "therapy": {
                "id": 3663,
                "therapyName": "Doxorubicin + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19404,
            "profileName": "RHEB over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19405,
            "profileName": "MYC rearrange RHEB over exp TP53 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}